Vascular Biogenics Ltd is an Israel-based clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
| Website: | www.vblrx.com |
| Email: | IR@VBLRX.COM |
| Main Phone: | +972 89935000 |
| Address: | 8 HaSatat Street |
| City / Town: | Modi'in |
| Country: | ISR |
| Postal Code: | 7178106 |
| Exchange: | NSD |
| CEO: | Dror Harats |
| Employees: | 39 |
| NAICS: | Pharmaceutical P |
Vascular Biogenics Ltd is an Israel-based clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
| Website: | www.vblrx.com |
| Email: | IR@VBLRX.COM |
| Main Phone: | +972 89935000 |
| Address: | 8 HaSatat Street |
| City / Town: | Modi'in |
| Country: | ISR |
| Postal Code: | 7178106 |
| Exchange: | NSD |
| CEO: | Dror Harats |
| Employees: | 39 |
| NAICS: | Pharmaceutical P |
| Last Price 1.40 | Change $ -0.03 | Change % -2.10 | Tick N/A |
| Bid 1.39 | Bid Size 13,000.00 | Ask 1.40 | Ask Size 4,100.00 |
| Open 1.39 | High 1.42 | Low 1.39 | Prev Close 1.43 |
| Last Trade | Volume 34,978 | 52 Wk Hi 1.90 | 52 Wk Low 0.94 |
| Market Cap 50.2 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 35,881,128.00 | EPS (TTM) -0.49 | PE Ratio N/A | Exchange NSD |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 3 | 3 | 3 | 3 |
| Low Target Price Estimate | 3 | 3 | 3 | 3 |
| Mean Target Price Estimate | 3 | 3 | 3 | 3 |
| Standard Deviation | 0 | 0 | 0 | 0 |
| Date of Most Recent Estimate | 03/11/18 | 03/11/18 | 03/11/18 | 03/11/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 4 | 2018-06-11 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 20 | 2018-05-17 |
| CT ORDER | 1 | 2018-04-27 | |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 10 | 2018-03-15 |
| 20-F | Annual and transition report of foreign private issuers under sections 13 or 15(d) | 337 | 2018-03-15 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 6 | 2018-03-08 |
| S-8 | Securities offered to employees under employee benefit plans | 9 | 2018-02-26 |
| SC 13D/A | Amendment to a SC 13D filing | 8 | 2018-02-21 |
| EFFECT | Notice from the SEC of registration effectiveness | 1 | 2018-01-04 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 6 | 2018-01-03 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 3 | 3 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 3 | 3 | 3 | 3 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait 